Mycoplasma genitalium
Mycoplasma genitalium

Mycoplasma genitalium is a small bacterium that is known to cause several sexually transmitted infections in humans. It is one of the smallest self-replicating bacteria identified and has a very limited genome.
Overview
Mycoplasma genitalium was first isolated in 1981. It is a pathogen that primarily infects the urogenital tract, leading to conditions like urethritis in men and cervicitis in women. It can also be associated with pelvic inflammatory disease.
Characteristics
This bacterium is characterized by its:
- Small size and lack of a cell wall
- Slow growth rate in laboratory cultures
- Ability to attach to epithelial cells in the urogenital tract
Transmission and Infection
Transmission of Mycoplasma genitalium is primarily through sexual contact. Infections can be symptomatic or asymptomatic, and chronic infections can lead to complications like infertility.
Diagnosis
Diagnosis of Mycoplasma genitalium infection involves:
- Polymerase chain reaction (PCR) testing to detect bacterial DNA in urine samples or genital swabs
- Molecular techniques for the determination of bacterial load in clinical samples
Treatment and Resistance
The treatment of Mycoplasma genitalium infections includes:
- Antibiotics such as azithromycin or doxycycline
- Emerging antibiotic resistance has become a significant concern, necessitating careful antibiotic selection
Epidemiology
While less common than other sexually transmitted infections, Mycoplasma genitalium is increasingly recognized as a cause of urogenital tract infections worldwide.
Public Health Implications
Due to its association with significant reproductive complications and emerging antibiotic resistance, Mycoplasma genitalium poses a public health challenge in managing sexually transmitted infections.
References
<references>
- "Mycoplasma genitalium: An Emerging Sexually Transmitted Infection" - National Center for Biotechnology Information
- "Sexually Transmitted Infections" - World Health Organization
</references>
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian



